ReviewFrontiers in microbiology2019
Nucleoside Analogues as Antibacterial Agents.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Drug repositioning: Progress and challenges in drug discovery for various diseases.European journal of medicinal chemistry · 2022Pooled it
- Engineering of a Nucleoside 2'-Deoxyribosyltransferase for Efficient Catalysis of 5-Halogenated-2'-Deoxypyrimidine Nucleosides via Active-Site Channel Expansion.Applied biochemistry and biotechnology · 2026Article
- LC-QTOF-MS metabolic profiling and anti-MRSA activity ofRSC advances · 2026Article
- De novo or Salvage? Nucleotide Availability as a Driver of Bacterial Adaptation and Virulence.MicrobiologyOpen · 2026Review
- A QM/MM study on triplet decay of 6-thioguanine and 6-selenoguanine with explicit solvent.Journal of molecular modeling · 2026Article
- Synthesis of Novel d-Glucopyranuronamide-Based Nucleos(t)ide Analogs Bearing (Triazolyl)methyl Phosph(on)ate Motifs With Anticancer and Antibacterial Potential.ChemMedChem · 2026Article
- Repurposing trifluridine as an anti-Staphylococcus aureus agent targeting virulence factor staphyloxanthin and attachment genes.Scientific reports · 2026Article
- Mechanistic insights into plasmid transfer inhibition in Enterobacterales by nucleoside analogues.npj antimicrobials and resistance · 2026Article
- (N)-Methanocarba Adenosine Derivatives as Dual Modulators of P-Glycoprotein and ABCG2 Transporters.Journal of medicinal chemistry · 2026Article
- TargetingFrontiers in microbiology · 2026Review
- Article
- Resensitizing the Untreatable: Zidovudine and Polymyxin Combinations to Combat Pan-Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
- DPAGT1-Perspective as an Anticancer Drug Target.Molecules (Basel, Switzerland) · 2025Review
- Label-free technique for universal and sequence independent detection of oligonucleotides and nuclease activity.Nucleic acids research · 2025Article
- Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2.The Journal of pharmacology and experimental therapeutics · 2025Article
- Uracil derivatives/ursolic acid hybrids - naturally derived compounds as anticancer agents.Scientific reports · 2025Article
- The impact of bacterial purine metabolism on antibiotic efficacy.npj antimicrobials and resistance · 2025Review
- Antifungal Activity of 5-Fluorouridine AgainstMolecules (Basel, Switzerland) · 2025Article
- Combinational Radiotherapies Improve Brain Cancer Treatment at High Dose Rates In Vitro.Cancers · 2025Article
- 5'-Guanidino Xylofuranosyl Nucleosides as Novel Types of 5'-Functionalized Nucleosides with Biological Potential.Pharmaceuticals (Basel, Switzerland) · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid increase in antibiotic-resistant bacteria has emphasized the urgent need to identify new treatments for bacterial infections. One attractive approach, reducing the need for expensive and time-consuming clinical trials, is to repurpose existing clinically approved compounds for use as antibacterial agents. Nucleoside analogues are commonly used for treating viral and fungal infections, as well as for treating cancers, but have received relatively little attention as treatments for bacterial infections. However, a significant number of clinically approved derivatives of both pyrimidines and purines including halogenated, thiolated, and azolated compounds have been shown to have antibacterial activity. In the small number of studies carried out to date, such compounds have shown promise in treating bacterial infections. Here, we review the mechanisms of action and antibacterial activities of nucleoside analogues that can potentially be repurposed for treating infections as well as considering possible limitations in their usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.